AmerisourceBergen’s Lash Group teams up with Medisafe to address patient adherence

Medcity | April 29, 2019

Through their alliance, Medisafe will deliver real-time interventions to help patients stay adherent and will alert Lash Group's clinicians when patients are considered at risk.

Spotlight

“When I walked into the room, the first thing I noticed was that these people didn’t look like me,” says Chelsea White, recalling her first group session with other HIV-positive patients.


Other News
FUTURE OF HEALTHCARE

TRC Healthcare Expands Portfolio with the Acquisition of QURE Healthcare

TRC Healthcare | March 16, 2022

TRC Healthcare a trusted leader in continuing education, has acquired QURE Healthcare, a recognized innovator in clinical measurement and quality improvement. QURE's provider-focused solutions lead to better patient outcomes and lower costs for healthcare systems and coverage and reimbursement for life-science clients. TRC's acquisition paves the way for QURE to scale its innovative Clinical Performance and Value (CPV®) patient simulation software solutions. "Through the acquisition, TRC Healthcare intends to augment its already robust suite of products by focusing on improving patient outcomes with evidence-based training, education and continuing education/continuing medical education for physicians and other providers" TRC Healthcare's CEO,Wes Crews, announced. "QURE is excited to join a company that is so aligned with our mission to raise the quality of healthcare, standardize practice and lower costs by changing clinician behavior. Measuring and reducing care variation using CPV®vignettes is QURE's core business. We have demonstrated in the peer-review literature that we can do this from the ambulatory to the intensive care setting and for diseases ranging from angina to zoonoses, all with the goal to eliminate unwarranted variation, raise quality for patients and lower costs for payers." Dr.John Peabody, the founder and president of QURE TRC Healthcare regards QURE as another key addition to its recent acquisition of NetCE, an industry leading continuing education platform that educates nurses, physicians, and mental health professionals. Together, QURE and NetCE fortify the evidence-based healthcare solutions TRC offers, "The addition of QURE increases our link between strong education and better patient outcomes," remarkedWes Crews. Dr. Peabody will continue to serve as QURE's President and will take on the additional role of Chief Medical Officer at TRC Healthcare. Dr. Peabody is a renowned international health care figure in clinical care quality and a professor at theUniversity of California, San FranciscoandLos Angeles. In 2012, John started QURE Healthcare. The QURE platform – CPV® vignettes – has grown and become a widely adopted standard for measuring clinical practice. QURE CPVs are used by organizations looking to engage their providers in clinical variation reduction efforts, including large health care systems, independent practice associations, public and private payers, governments, non-governmental associations, and intergovernmental organizations. Dr. Peabody has contributed more than 200 articles, books, and abstracts to the peer-review literature, served on blue ribbon committees, testified before congress and advised heads of state on a wide variety of subjects notably quality improvement and the economic benefits of standardizing practice in healthcare systems. "QURE is an extraordinary company, with a validated product and team and an incredibly passionate community of users," saidWes Crews. "Together we can transform the way we engage providers and change patient care." About TRC Healthcare TRC Healthcare (TRC) is a premier source of lifelong learning solutions for healthcare professionals. TRC is most recognized for their education and CE offerings within the highly-regarded Pharmacist's Letter, Prescriber's Letter, and Pharmacy Technician's Letter. TRC also offers Pharmacy Technicians University, the leading online training program for pharmacy technicians. The Natural Medicines database makes it easy for subscribers to find unbiased, evidenced-based research about alternative drug therapies. Through the acquisition of CriticalPoint, NetCE and Bula TRC Healthcare has been expanding its offerings. CriticalPoint increases patient safety through a variety of educational compounding offerings concentrating on USP 797, 800, and 795. NetCE is an industry-leading, continuing- education platform supporting multiple professions including nurses, physicians, and mental health. And Bula provides legal and regulatory advice to retail pharmacies. These additions give TRC Healthcare the industry's largest catalog of continuing education and advisory services, with thousands of courses trusted by healthcare professionals to provide accredited training that meets continuing education and licensing requirements. About QURE QURE Healthcare is a provider engagement company committed to improving the quality of clinical care. using its proprietary technology, CPV®(Clinical Performance and Value) vignettes. CPV®vignettes

Read More

MEDICAL DEVICES

MedTech Company STENTiT Raises €1.8 million in Seed Round

STENTiT | April 25, 2022

STENTiT, a medical device company bringing a novel class of regenerative endovascular implants for the treatment of cardiovascular diseases, has closed a €1.8 million seed investment round. The funding facilitates further pre-clinical development and batch production of a regenerative stent (see video) for peripheral indications. The investment was made by Dutch investors NextGen Ventures, Brabant Development Agency and the Ten Cate Investment Company. STENTiT is an emerging player in the field of regenerative medical devices, offering a breakthrough solution for cardiovascular interventions by developing first-of-its-kind endovascular implants with regenerative capacity. Using a catheter-based approach, these devices provide the ability to restore arteries without the need for an invasive surgical intervention. The aim is to ultimately restore the affected blood vessel from the inside out to provide a lifelong solution. As a first target indication, the company wants to improve the treatment of critical limb ischemia. This progressive form of peripheral artery disease affects almost 5 million people in the EU and the US in which the blood flow to the foot is severely being compromised. Unfortunately, current treatment options are ineffective, resulting in amputation within 6 months in 40% of these patients. With the regenerative stent, blood flow to the foot will be maintained by securing vascular patency using temporary mechanical support and improving long-term efficacy by inducing vascular repair, thereby preventing thousands of amputations each year. "We are excited to receive the support of these esteemed Dutch early-stage investors. This financing round validates our vision to bring a novel class of implants that can rebuild the affected blood vessels. We are looking forward taking the next steps getting our regenerative stents ready for clinical trials. With our first product, we aim to treat millions of patients suffering from peripheral artery diseases, and save their limbs from amputation." Bart Sanders, CEO of STENTiT About STENTiT STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out. Since the establishment of the company, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-changing solution for millions of cardiovascular patients around the world.

Read More

HEALTH TECHNOLOGY

Frost & Sullivan Awards proteanTecs Best Electronics Health Monitoring Technology

proteanTecs | December 23, 2021

proteanTecs, a leading developer of deep data analytics solutions for electronics health and performance monitoring, announced today it has won the 2021 Frost & Sullivan Best Practices Award for Global Electronics Health Monitoring Technology Innovation Leadership.Electronics have become an existential enabler for key industries, from Datacenter to Automotive, where 24/7 continuity with zero in-mission failures is pivotal. Therefore, it is necessary to guarantee these systems' reliability, bringing a key question to the fore: How can service providers, such as data center hyperscalers and car OEMs, track the health of electronic fleets working under extreme conditions while ensuring business resilience until the devices complete their lifetime? The award reviews the evolving landscape of electronics and presents the clear and critical need for deep data analytics across multiple industries and mission critical devices. The award declares, "Electronics health monitoring is essential to ensure these systems' functional continuity and reliability. proteanTecs offers a unique value proposition in the form of on-chip agents capable of extracting parametric data in various lifecycle stages. The Universal Chip Telemetry (UCT) enabled Proteus deep data analytics platform provides actionable insights and alerts to users along the value chain based on common, correlated, and predictive data. This allows users to take immediate action to ensure uptime and improve power, performance, and reliability." "By weaving data science together with on-chip visibility, proteanTecs' solutions deliver an unprecedented clarity at each step of the system's lifecycle", observed Sushrutha Sadashiva, Industry Analyst. "Frost & Sullivan presents Best Practices Awards to companies that inspire growth in their industries. These leaders identify emerging trends before they become the market standard and create solutions that drive differentiation and sustainable growth. They are the game changers," said Jeff Frigstad, Global Sr. Vice President, Best Practices, Frost & Sullivan. Frost & Sullivan applies a rigorous process to evaluate multiple nominees for each award category, with a detailed evaluation of best practice criteria across several dimensions. "Frost & Sullivan is at the center of the ecosystem for best practice cultivation, with cutting-edge insights that are singularly focused on reshaping the world through managed growth. It is a great honor to be recognized by them as the technology innovation leader in the Global Electronics Health Monitoring industry." Shai Cohen, proteanTecs co-founder and CEO About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 60 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. About proteanTecs proteanTecs is a leading provider of deep data monitoring solutions for advanced electronics in the Datacenter, Automotive, Communications and Mobile markets. Based on Universal Chip Telemetry™ (UCT), the company provides system health and performance monitoring, from production to the field. By applying machine learning to novel data created by on-chip UCT agents, the company's analytics platform delivers predictive insights and visibility, leading to new levels of quality, reliability and scale. Founded in 2017, the company is headquartered in Israel with offices in New Jersey, California, India and Taiwan.

Read More

INSURANCE

Exela Expands PCH Global Solution with Leading Healthcare Insurer

Exela Technologies | January 12, 2022

Exela Technologies, Inc. (“Exela”)today announced that it continues to expand its relationship with a leading health insurance organization that spans almost two decades. This customer continues to accelerate deployment of Exela’s PCH Global platform to speed up their digital transformation and improve both the member and provider experience. The latest expansion is valued at $6.2 million of additional contract value revenue. Exela continues to invest in expanding PCH Global’s capabilities to provide a cloud hosted solution with one of the best edit resolutions for healthcare claims. This extension of deployment marks another milestone in the value proposition of the PCH Global platform to digitally connect members, providers and insurance companies to enable clean claims, payment transparency and digital appeals. PCH Global’s cloud network also offers increased scalability, the highest uptime and best business continuity protections. PCH Global has robust data analytics which are continually improving as Exela processes more and more data. Additionally, PCH Global’s improved data analytics can be accessed via a self-service model. “We are proud of our long standing partnership and privileged to be part of customer’s digital transformation journey. Adoption of our PCH Global platform continues to address healthcare industry’s goal to deliver most efficient, cost effective and best healthcare to the members.” Suresh Yannamani, President of Exela About Exela Technologies Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of experience operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune® 100. Utilizing foundational technologies spanning information management, workflow automation, and integrated communications, Exela’s software and services include multi-industry, departmental solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and the public sector. Through cloud-enabled platforms, built on a configurable stack of automation modules, and over 17,500 employees operating in 23 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner.

Read More